Skip to content
TriangleGet started
← Full study record

NCT00866047 · FLOW

Participant flow

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma · Source last updated 2017-03-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Brentuximab vedotin 1.8 mg/kg every 3 weeks by intravenous (IV) infusion
    id
    FG000
    title
    Brentuximab Vedotin
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        13
      type
      Progressive disease
    2. reasons
      1. group Id
        FG000
        num Subjects
        16
      type
      Adverse Event
    3. reasons
      1. group Id
        FG000
        num Subjects
        14
      type
      Physician Decision
    4. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Withdrawal by Subject
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        58
      type
      STARTED
    2. achievements
      1. comment
        Number who completed 16 cycles of treatment
        group Id
        FG000
        num Subjects
        10
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        48
      type
      NOT COMPLETED
    title
    Treatment Period
  2. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Lost to Follow-up
    milestones
    1. achievements
      1. comment
        All participants were to be followed after treatment
        group Id
        FG000
        num Subjects
        58
      type
      STARTED
    2. achievements
      1. comment
        Completed survival follow-up due to death \[25\] or study completion \[28\]
        group Id
        FG000
        num Subjects
        53
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        5
      type
      NOT COMPLETED
    title
    Follow-up Period
recruitment Details
Enrollment period: Jun 2009 - May 2010
Complete source fields
groups
  1. description
    Brentuximab vedotin 1.8 mg/kg every 3 weeks by intravenous (IV) infusion
    id
    FG000
    title
    Brentuximab Vedotin
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        13
      type
      Progressive disease
    2. reasons
      1. group Id
        FG000
        num Subjects
        16
      type
      Adverse Event
    3. reasons
      1. group Id
        FG000
        num Subjects
        14
      type
      Physician Decision
    4. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Withdrawal by Subject
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        58
      type
      STARTED
    2. achievements
      1. comment
        Number who completed 16 cycles of treatment
        group Id
        FG000
        num Subjects
        10
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        48
      type
      NOT COMPLETED
    title
    Treatment Period
  2. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        5
      type
      Lost to Follow-up
    milestones
    1. achievements
      1. comment
        All participants were to be followed after treatment
        group Id
        FG000
        num Subjects
        58
      type
      STARTED
    2. achievements
      1. comment
        Completed survival follow-up due to death \[25\] or study completion \[28\]
        group Id
        FG000
        num Subjects
        53
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        5
      type
      NOT COMPLETED
    title
    Follow-up Period
recruitment Details
Enrollment period: Jun 2009 - May 2010

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Independent clinical review pending · Not medical advice